Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 111


Preclinical Testing of an Oncolytic Parvovirus in Ewing Sarcoma: Protoparvovirus H-1 Induces Apoptosis and Lytic Infection In Vitro but Fails to Improve Survival In Vivo.

Lacroix J, Kis Z, Josupeit R, Schlund F, Stroh-Dege A, Frank-Stöhr M, Leuchs B, Schlehofer JR, Rommelaere J, Dinsart C.

Viruses. 2018 Jun 3;10(6). pii: E302. doi: 10.3390/v10060302.


Immunotherapeutic Potential of Oncolytic H-1 Parvovirus: Hints of Glioblastoma Microenvironment Conversion towards Immunogenicity.

Angelova AL, Barf M, Geletneky K, Unterberg A, Rommelaere J.

Viruses. 2017 Dec 15;9(12). pii: E382. doi: 10.3390/v9120382.


Canine Parvovirus ns1 gene and Chicken Anemia vp3 gene induce partial oncolysis of Canine Transmissible Venereal Tumor.

Bhat AH, Ganguly B, Tiwari AK, Das AK.

Sci Rep. 2017 Nov 13;7(1):15419. doi: 10.1038/s41598-017-15734-6.


Atomic Resolution Structure of the Oncolytic Parvovirus LuIII by Electron Microscopy and 3D Image Reconstruction.

Pittman N, Misseldine A, Geilen L, Halder S, Smith JK, Kurian J, Chipman P, Janssen M, Mckenna R, Baker TS, D'Abramo A Jr, Cotmore S, Tattersall P, Agbandje-McKenna M.

Viruses. 2017 Oct 30;9(11). pii: E321. doi: 10.3390/v9110321.


Protoparvovirus Cell Entry.

Ros C, Bayat N, Wolfisberg R, Almendral JM.

Viruses. 2017 Oct 26;9(11). pii: E313. doi: 10.3390/v9110313. Review.


Preclinical Testing of an Oncolytic Parvovirus: Standard Protoparvovirus H-1PV Efficiently Induces Osteosarcoma Cell Lysis In Vitro.

Geiss C, Kis Z, Leuchs B, Frank-Stöhr M, Schlehofer JR, Rommelaere J, Dinsart C, Lacroix J.

Viruses. 2017 Oct 17;9(10). pii: E301. doi: 10.3390/v9100301.


Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial.

Geletneky K, Hajda J, Angelova AL, Leuchs B, Capper D, Bartsch AJ, Neumann JO, Schöning T, Hüsing J, Beelte B, Kiprianova I, Roscher M, Bhat R, von Deimling A, Brück W, Just A, Frehtman V, Löbhard S, Terletskaia-Ladwig E, Fry J, Jochims K, Daniel V, Krebs O, Dahm M, Huber B, Unterberg A, Rommelaere J.

Mol Ther. 2017 Dec 6;25(12):2620-2634. doi: 10.1016/j.ymthe.2017.08.016. Epub 2017 Aug 24.


Virotherapy Research in Germany: From Engineering to Translation.

Ungerechts G, Engeland CE, Buchholz CJ, Eberle J, Fechner H, Geletneky K, Holm PS, Kreppel F, Kühnel F, Lang KS, Leber MF, Marchini A, Moehler M, Mühlebach MD, Rommelaere J, Springfeld C, Lauer UM, Nettelbeck DM.

Hum Gene Ther. 2017 Oct;28(10):800-819. doi: 10.1089/hum.2017.138.


A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer: ParvOryx02 protocol.

Hajda J, Lehmann M, Krebs O, Kieser M, Geletneky K, Jäger D, Dahm M, Huber B, Schöning T, Sedlaczek O, Stenzinger A, Halama N, Daniel V, Leuchs B, Angelova A, Rommelaere J, Engeland CE, Springfeld C, Ungerechts G.

BMC Cancer. 2017 Aug 29;17(1):576. doi: 10.1186/s12885-017-3604-y.


Gene Therapy for Pancreatic Cancer: Specificity, Issues and Hopes.

Rouanet M, Lebrin M, Gross F, Bournet B, Cordelier P, Buscail L.

Int J Mol Sci. 2017 Jun 8;18(6). pii: E1231. doi: 10.3390/ijms18061231. Review.


The Oncolytic Virotherapy Era in Cancer Management: Prospects of Applying H-1 Parvovirus to Treat Blood and Solid Cancers.

Angelova AL, Witzens-Harig M, Galabov AS, Rommelaere J.

Front Oncol. 2017 May 12;7:93. doi: 10.3389/fonc.2017.00093. eCollection 2017.


Oncolytic viral therapy for pancreatic cancer.

Rahal A, Musher B.

J Surg Oncol. 2017 Jul;116(1):94-103. doi: 10.1002/jso.24626. Epub 2017 Apr 13. Review.


Oncolytic Virotherapy for the Treatment of Malignant Glioma.

Foreman PM, Friedman GK, Cassady KA, Markert JM.

Neurotherapeutics. 2017 Apr;14(2):333-344. doi: 10.1007/s13311-017-0516-0. Review.


A novel scalable, robust downstream process for oncolytic rat parvovirus: isoelectric point-based elimination of empty particles.

Leuchs B, Frehtman V, Riese M, Müller M, Rommelaere J.

Appl Microbiol Biotechnol. 2017 Apr;101(8):3143-3152. doi: 10.1007/s00253-016-8071-x. Epub 2017 Jan 14.


Recombinant Parvoviruses Armed to Deliver CXCL4L1 and CXCL10 Are Impaired in Their Antiangiogenic and Antitumoral Effects in a Kaposi Sarcoma Tumor Model Due To the Chemokines' Interference with the Virus Cycle.

Dinsart C, Pervolaraki K, Stroh-Dege A, Lavie M, Ronsse I, Rommelaere J, Van Damme J, Van Raemdonck K, Struyf S.

Hum Gene Ther. 2017 Mar;28(3):295-306. doi: 10.1089/hum.2016.108. Epub 2016 Dec 29.


Serine protease inhibitor kazal-type 6 inhibits tumorigenesis of human hepatocellular carcinoma cells via its extracellular action.

Ge K, Huang J, Wang W, Gu M, Dai X, Xu Y, Wu H, Li G, Lu H, Zhong J, Huang Q.

Oncotarget. 2017 Jan 24;8(4):5965-5975. doi: 10.18632/oncotarget.13983.


Parvovirus Capsid Structures Required for Infection: Mutations Controlling Receptor Recognition and Protease Cleavages.

Callaway HM, Feng KH, Lee DW, Allison AB, Pinard M, McKenna R, Agbandje-McKenna M, Hafenstein S, Parrish CR.

J Virol. 2017 Jan 3;91(2). pii: e01871-16. doi: 10.1128/JVI.01871-16. Print 2017 Jan 15.


A generic viral dynamic model to systematically characterize the interaction between oncolytic virus kinetics and tumor growth.

Titze MI, Frank J, Ehrhardt M, Smola S, Graf N, Lehr T.

Eur J Pharm Sci. 2017 Jan 15;97:38-46. doi: 10.1016/j.ejps.2016.11.003. Epub 2016 Nov 5.


Poly (I:C) enhances the anti-tumor activity of canine parvovirus NS1 protein by inducing a potent anti-tumor immune response.

Gupta SK, Yadav PK, Tiwari AK, Gandham RK, Sahoo AP.

Tumour Biol. 2016 Sep;37(9):12089-12102. Epub 2016 May 21.


A new protoparvovirus in human fecal samples and cutaneous T cell lymphomas (mycosis fungoides).

Phan TG, Dreno B, da Costa AC, Li L, Orlandi P, Deng X, Kapusinszky B, Siqueira J, Knol AC, Halary F, Dantal J, Alexander KA, Pesavento PA, Delwart E.

Virology. 2016 Sep;496:299-305. doi: 10.1016/j.virol.2016.06.013. Epub 2016 Jul 7.

Supplemental Content

Loading ...
Support Center